These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35056015)

  • 1. Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients.
    Boedecker-Lips SC; Lautem A; Runkel S; Klimpke P; Kraus D; Keil P; Holtz S; Tomalla V; Marczynski P; Boedecker CB; Galle PR; Koch M; Weinmann-Menke J
    Pathogens; 2022 Jan; 11(1):. PubMed ID: 35056015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients.
    Graninger M; Stumpf J; Bond G; Görzer I; Springer DN; Kessel F; Kröger H; Frank K; Tonn T; Hugo C; Puchhammer-Stöckl E
    J Clin Virol; 2023 May; 162():105428. PubMed ID: 36989730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.
    Bertrand D; Hamzaoui M; Lemée V; Lamulle J; Hanoy M; Laurent C; Lebourg L; Etienne I; Lemoine M; Le Roy F; Nezam D; Plantier JC; Boyer O; Guerrot D; Candon S
    J Am Soc Nephrol; 2021 Sep; 32(9):2147-2152. PubMed ID: 34112706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Stumpf J; Anders L; Siepmann T; Schwöbel J; Karger C; Lindner T; Faulhaber-Walter R; Langer T; Escher K; Anding-Rost K; Seidel H; Hüther J; Pistrosch F; Martin H; Schewe J; Stehr T; Meistring F; Paliege A; Schneider D; Bast I; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Skrzypczyk S; Anft M; Klimova A; Mauer R; Roeder I; Tonn T; Babel N; Hugo C
    Vaccine; 2024 Jan; 42(2):120-128. PubMed ID: 38114410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type.
    Stumpf J; Schwöbel J; Karger C; Schirutschke H; Mauer R; Klimova A; Tonn T; Hugo C
    Front Med (Lausanne); 2022; 9():910987. PubMed ID: 35860743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients.
    La Civita E; Zannella C; Brusa S; Romano P; Schettino E; Salemi F; Carrano R; Gentile L; Punziano A; Lagnese G; Spadaro G; Franci G; Galdiero M; Terracciano D; Portella G; Loffredo S
    Viruses; 2023 Jul; 15(8):. PubMed ID: 37632002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients.
    Ohki Y; Kawabe M; Yamamoto I; Katsumata H; Nakada Y; Kobayashi A; Urabe F; Miki J; Yamada H; Kimura T; Matsuo N; Tanno Y; Horino T; Ohkido I; Yamamoto H; Yokoo T
    Front Microbiol; 2022; 13():922042. PubMed ID: 35756063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients.
    Pérez-Flores I; Juarez I; Aiffil Meneses AS; Lopez-Gomez A; Romero NC; Rodriguez-Cubillo B; Moreno de la Higuera MA; Peix-Jiménez B; Gonzalez-Garcia R; Baos-Muñoz E; Vilela AA; Gómez Del Moral M; Martínez-Naves E; Sanchez-Fructuoso AI
    Front Immunol; 2023; 14():1111569. PubMed ID: 36817489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
    Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
    Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis.
    Jahn M; Korth J; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Tyczynski B; Gäckler A; Witzke O; Dittmer U; Dolff S; Wilde B; Kribben A
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33918085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
    Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J
    Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients.
    Netti GS; Infante B; Troise D; Mercuri S; Panico M; Spadaccino F; Catalano V; Gigante M; Simone S; Pontrelli P; Gesualdo L; Ranieri E; Castellano G; Stallone G
    Am J Transplant; 2022 May; 22(5):1475-1482. PubMed ID: 35038362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
    Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
    J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
    Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
    Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant.
    Del Mastro A; Picascia S; D'Apice L; Trovato M; Barba P; Di Biase I; Di Biase S; Laccetti M; Belli A; Amato G; Di Muro P; Credendino O; Picardi A; De Berardinis P; Del Pozzo G; Gianfrani C
    Viruses; 2023 May; 15(5):. PubMed ID: 37243218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.
    Cappuccilli M; Semprini S; Fabbri E; Fantini M; Bruno PF; Spazzoli A; Righini M; Flachi M; La Manna G; Sambri V; Mosconi G
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888612
    [No Abstract]   [Full Text] [Related]  

  • 17. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.
    Rincon-Arevalo H; Choi M; Stefanski AL; Halleck F; Weber U; Szelinski F; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Potekhin A; Chen Y; Burmester GR; Eckardt KU; Guerra GM; Durek P; Heinrich F; Ferreira-Gomes M; Radbruch A; Budde K; Lino AC; Mashreghi MF; Schrezenmeier E; Dörner T
    Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34131023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study-The COViNEPH Project.
    Dębska-Ślizień A; Ślizień Z; Muchlado M; Kubanek A; Piotrowska M; Dąbrowska M; Tarasewicz A; Chamienia A; Biedunkiewicz B; Renke M; Tylicki L
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.
    Yanis A; Haddadin Z; Spieker AJ; Waqfi D; Rankin DA; Talj R; Thomas L; Birdwell KA; Ezzell L; Blair M; Eason J; Varjabedian R; Warren CM; Nochowicz CH; Olson EC; Simmons JD; Yoder S; Guy M; Thomsen I; Chappell JD; Kalams SA; Halasa NB
    Transpl Infect Dis; 2022 Feb; 24(1):e13772. PubMed ID: 34905653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.